About | Speaker | Programme | Registration | Sponsoring
Regenerative Medicine - An Industry Perspective
Novel therapeutic approaches in Regenerative Medicine aiming to replace or regenerate diseased tissue have vast potential to tackle unmet patient needs.
Progress in this field is naturally is being born out of research by academia. The impact of commercial development in this sector is yet to be observed on a grand scale, mainly due to the nature of the discipline still very much in the R&D phase.
Top left - Samantha Paulsen a graduate student in the Jordan Miller lab at Rice University displays a plate on which 3D printed silicone templates have been mounted. In this picture the hollow moulds have been injected with a red dye to better show the pattern of small vessels inside . Credit: Jeff Fitlow/Rice University.
Top Right - 3D printed networks Endothelial cells, the building blocks of capillaries, veins and arteries (red) line the walls of Miller’s 3D–printed vascular structures . Credit [Jordan Miller/The Scientist].
Bottom Left - At the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, scientists use a specifically-modified 3D printer to build scaffolding for biomaterials that may one day be used to create organs, tissues and bones for human transplant. Credit: NJTV.
Bottom Right - Hyun-Wook Kang, a postdoctoral fellow at Wake Forest Institute uses a 3D printer that is making a kidney prototype with cells and scaffold biomaterials . Credit: Wake Forest Institute of Regenerative Medicine.
WHAT CAN WE EXPECT OF THE PHARMA INDUSTRY IN TERMS OF MAKING STRONG HEADWAY IN R&D WITHIN REGENERATIVE MEDICINE?
According to current estimates, with over 700 companies worldwide and an equal number of clinical trials underway, the global Regenerative Medicine market is worth approximately $20 billion and is expected to grow at an impressive compound annual growth rate of 20% by the 2020s [3-5].
A key growth driver for this market is the increased focus on cell therapy products, which owes to the rise in demand, increased investments from pharmaceutical and biotechnology companies, and government initiatives . However, some of the persistent challenges that hamper market growth is a strict regulatory framework, the cost of manufacturing and high failure rates in clinical trials .
WHAT CAN BE DONE TO IMPROVE THE CLINICAL AND COMMERCIAL OUTCOME OF REGENERATIVE MEDICINE THERAPIES?
WHAT MAJOR DEVELOPMENTS IN REGENERATIVE MEDICINE WILL THE NEXT 10 YEARS BRING?
WHAT CAN THE GOVERNMENT, INDUSTRY AND ACADEMIA DO FOR THE UK TO STAY AT THE FOREFRONT OF REGENERATIVE MEDICINE?
 Annual Data Report on gene and cellular therapies and the regenerative medicine sector. Alliance for Regeneretive Medicine. 2015
 Report Regenerative Medicines Market by Therapy - Global Forecast to 2021. MarketsandMarkets
 Report Global Regenerative Medicine Market 2016-2020. Technavio
 Report World Preview 2016, Outlook to 2022. EvaluatePharma
 Culme-Seymour EJ, Davie NL, Brindley DA, Edwards-Parton S, Mason C. A decade of cell therapy clinical trials (2000-2010). Regen Med. 2012; 7(4):455-62.